---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-105923"
form_type: "8-K"
ticker: "VSTM"
cik: "0001526119"
company_name: "Verastem, Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:36:46.447049+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Verastem posts $11.2M Q3 product revenue, GAAP net loss $98.5M

## Summary
- AVMAPKI FAKZYNJA CO-PACK achieved $11.2 million net product revenue in first full quarter of launch.
- GAAP net loss $98.5M ($1.35/share) vs $24.0M ($0.60) YoY; non-GAAP adjusted net loss $39.4M ($0.54/share).
- Cash $137.7M; with product revenue and warrant exercises, runway into H2 2026.
- VS-7375 cleared 400 mg and 600 mg QD monotherapy with no DLTs; no nausea/vomiting/diarrhea >Grade 1.
- RAMP 301 (LGSOC) completed targeted enrollment of 270 patients early; IDMC recommended 29 additional patients.

## SEC filing metadata
- accession: 0001104659-25-105923
- form_type: 8-K
- ticker: VSTM
- cik: 0001526119
- company_name: Verastem, Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1526119/000110465925105923/0001104659-25-105923-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1526119/000110465925105923/tm2530140d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-105923
- JSON: https://secwatch.observer/filing/0001104659-25-105923.json
- Plain text: https://secwatch.observer/filing/0001104659-25-105923.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.